| Jun'18 | Jun'17 | Jun'16 | Jun'15 | ||
|---|---|---|---|---|---|
Research and development expenses, net | |||||
0 | 0 | 0 | 0 | ||
General and administrative expenses | |||||
0 | 0 | 0 | 0 | ||
Operating loss | |||||
0 | 0 | 0 | 0 | ||
Finance income (expenses), net | |||||
0 | 0 | 0 | 0 | ||
Loss before tax | |||||
0 | 0 | 0 | - | ||
Taxes on income | |||||
0 | 0 | 0 | - | ||
Net loss for the period | |||||
0 | 0 | 0 | 0 | ||
Net loss per ordinary share basic and diluted | |||||
0.70 | 2.02 | 0.15 | 0.18 | ||
Weighted average number of ordinary shares outstanding - basic and diluted (in thousands) | |||||
3,796,000 | 1,403,000 | 13,274,000 | 13,266 | ||